The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

Stifel Nicolaus analyst James Condulis maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $80.00.

A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...